Logo

Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders

Share this

Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders

Shots:

  • Bayer and Kyoto University collaborate to jointly conduct clinical trials for identifying targets in lung diseases. Bayer will have an exclusive option to license the developed product in the trial
  • The focus of the agreement is to discover targets and develop treatments- with combined techniques of the company in pulmonary disorders including idiopathic pulmonary fibrosis (IPF)
  • In 2014- Bayer and Kyoto University's Office of Society-Academia Collaboration for Innovation (KU-SACI) collaborated to jointly explore candidates for certain research projects in areas cardiology & oncology including hematology- gynecology- and ophthalmology

Ref: Bayer | Image: Bayer


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions